Surrozen, Inc. (NASDAQ:SRZN) Receives Average Recommendation of “Moderate Buy” from Analysts

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $42.00.

Several analysts have commented on SRZN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Surrozen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Zacks Research downgraded shares of Surrozen from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price target (up from $36.00) on shares of Surrozen in a report on Thursday, May 7th.

Get Surrozen alerts:

Check Out Our Latest Analysis on SRZN

Insider Transactions at Surrozen

In related news, CEO Craig C. Parker sold 4,524 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $33.33, for a total transaction of $150,784.92. Following the transaction, the chief executive officer directly owned 16,553 shares of the company’s stock, valued at $551,711.49. This represents a 21.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Charles O. Williams sold 2,036 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the sale, the chief operating officer owned 16,571 shares of the company’s stock, valued at approximately $552,311.43. This trade represents a 10.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,144 shares of company stock valued at $271,440 in the last quarter. 31.74% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Surrozen

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. Citadel Advisors LLC boosted its stake in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Surrozen during the 4th quarter worth approximately $99,000. Schonfeld Strategic Advisors LLC increased its stake in Surrozen by 8.1% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 74,645 shares of the company’s stock valued at $1,687,000 after purchasing an additional 5,621 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Price Performance

Surrozen stock opened at $24.92 on Friday. Surrozen has a twelve month low of $8.00 and a twelve month high of $35.00. The business has a fifty day moving average of $26.39 and a two-hundred day moving average of $25.23. The firm has a market cap of $289.32 million, a P/E ratio of -0.66 and a beta of 0.51.

Surrozen (NASDAQ:SRZN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $4.00 million. Equities analysts expect that Surrozen will post -7.2 earnings per share for the current year.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

Featured Articles

• Five stocks we like better than Surrozen
• These Stocks Could Win as Wall Street Looks Beyond AI Software
• D.R. Horton Is Defying the Housing Gloom
• Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
• Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.